Akebia Therapeutics (NASDAQ:AKBA) Big Money Quarterly Sentiment at 0.89

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Corporate Logo

Akebia Therapeutics’s Sentiment

“Big money sentiment for Akebia Therapeutics (NASDAQ:AKBA) in 2018 Q3 decreased to 0.89, SEC.gov filings reveal. So its down -0.46, from 2018Q2’s 1.35. 49 hedge funds increased and started new stock positions, while 55 sold and reduced stakes in Akebia Therapeutics so the sentiment worsened. Funds own 38.94 million shares, down from 39.91 million shares in 2018Q2. Funds holding Akebia Therapeutics in top 10 changed to 1 from 2 for a decrease of 1. 19 Investors Sold All; 36 Reduced Holdings; 34 increased holdings while 15 hedge funds bought holdings.

Significant Akebia Therapeutics Investors

Dafna Capital Management Llc owns 625,738 shares in Akebia Therapeutics as of 2018 Q3. Akebia Therapeutics’s shareholder Nantahala Capital Management Llc owns 4.72 million shares as of 2018 Q3. Moreover, Opus Point Partners Management Llc reported 45,004 shares in Akebia Therapeutics equivalent to 0.95% of its fund’s portfolio. Stanley revealed 301,182 shares position in Akebia Therapeutics. The New York-based fund Perceptive Advisors Llc holds 2.45 million shares or 0.58% of their fund’s portfolio.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor biology.The firm is valued at $728.21 million. The Company’s lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients.Last it reported negative earnings. The firm is also developing a HIF portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease.

The stock decreased 0.95% or $0.06 during the last trading session, reaching $6.23.Currently Akebia Therapeutics, Inc. is downtrending after 42.65% change in last January 14, 2018. AKBA has also 534,157 shares volume. AKBA underperformed by 42.65% the S&P500.

On March, 11 is expected Akebia Therapeutics, Inc. (NASDAQ:AKBA)’s earnings report, according to Zacks. EPS of $-0.80 is 420.00 % down from 2018’s $0.25 EPS. Analysts at Wall Street see Akebia Therapeutics, Inc.’s 73.91 % negative EPS growth compared to $-0.46 EPS for previous quarter.

Deutsche Fincl Bank Ag invested 0% of its capital in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Stratos Wealth Prtnrs Limited holds 0% in Akebia Therapeutics, Inc. (NASDAQ:AKBA) or 90 shs. Spark Limited Liability Corp has 0.15% invested in Akebia Therapeutics, Inc. (NASDAQ:AKBA). State Street Corp invested 0% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Quantitative Systematic Strategies Lc invested in 0.04% or 22,925 shs. Horizon Kinetics Lc has 0.01% invested in Akebia Therapeutics, Inc. (NASDAQ:AKBA) for 51,676 shs. Renaissance Technology Ltd Company stated it has 0.02% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Creative Planning owns 10,650 shs or 0% of their US capital. Bnp Paribas Arbitrage Sa invested 0% of its capital in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Sg Americas Lc holds 0.01% or 79,629 shs in its capital. California-based Dafna Capital Mngmt Limited Liability Com has invested 2.27% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Alps Advisors, Colorado-based fund reported 100,948 shs. Abrams Lp has invested 0.26% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Perceptive Advsrs Ltd, a New York-based fund reported 2.45M shs. 156,266 are held by State Of Wisconsin Invest Board.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Ratings Coverage

In total 2 analysts cover Akebia Therapeutics (NASDAQ:AKBA). “Buy” rating has 1, “Sell” are 0, while 1 are “Hold”. (NASDAQ:AKBA) has 50% bullish analysts. 2 are the (NASDAQ:AKBA)’s ratings reports on 14 Jan 2019 according to StockzIntelligence Inc. On Friday, September 7 the rating was maintained by Morgan Stanley with “Equal-Weight”.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.